Molecular Epidemiology of Benzene-exposed Workers.

NCT ID: NCT00364520

Last Updated: 2015-05-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-08-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the health effects of benzene exposure in workers in Shanghai, China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate the dose-response relationship between benzene exposure and blood diseases in Shanghai workers and to characterize genetic polymorphisms that are associated with increased risk of developing benzene hematotoxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shanghai Workers

Shanghai Workers

Shanghai workers

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Shanghai workers

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Worked for at least one year in a monitored environment Have at least one physical examination recorded

\-

Exclusion Criteria

History of cancer, radiation exposure, chemotherapy

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

67 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fudan University

OTHER

Sponsor Role collaborator

University of Cincinnati

OTHER

Sponsor Role collaborator

ExxonMobil Biomedical Sciences, Inc.

INDUSTRY

Sponsor Role collaborator

British Petroleum P.L.C.

INDUSTRY

Sponsor Role collaborator

Chevron Corporation

INDUSTRY

Sponsor Role collaborator

ConocoPhillips

INDUSTRY

Sponsor Role collaborator

Exxon Mobil

INDUSTRY

Sponsor Role collaborator

Marathon Ashland

UNKNOWN

Sponsor Role collaborator

Shell Chemicals

INDUSTRY

Sponsor Role collaborator

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard D Irons, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado at Denver and Health Sciences Ctr

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Joint Sino-US Clinical and Molecular Laboratory (JCML)

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

02-0037

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ultralow Dose PAH Binary Mixture Study
NCT03631667 COMPLETED EARLY_PHASE1